Inactive Instrument

Fresenius SE & Co. KGaA Share Price Other OTC

Equities

FSNUY

US35804M1053

Healthcare Facilities & Services

Financials

Sales 2024 * 22.96B 24.47B 2,046B Sales 2025 * 24.06B 25.65B 2,144B Capitalization 15.75B 16.79B 1,404B
Net income 2024 * 1.45B 1.55B 129B Net income 2025 * 1.78B 1.9B 159B EV / Sales 2024 * 1.31 x
Net Debt 2024 * 14.27B 15.21B 1,272B Net Debt 2025 * 13.48B 14.37B 1,201B EV / Sales 2025 * 1.22 x
P/E ratio 2024 *
10.7 x
P/E ratio 2025 *
8.78 x
Employees -
Yield 2024 *
3.34%
Yield 2025 *
3.79%
Free-Float 73.04%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Fresenius SE & Co. KGaA

Managers TitleAgeSince
Chief Executive Officer 55 12/21/12
Director of Finance/CFO 44 01/19/01
Compliance Officer - 18/23/18
Members of the board TitleAgeSince
Director/Board Member 69 20/15/20
Chairman 69 01/20/01
Director/Board Member 63 13/16/13
More insiders
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).
Calendar
More about the company